Progress on ABN AMRO share buyback programme 8 April – 14 April 2022
Progress on ABN AMRO share buyback programme 8April – 14April2022
ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 9 February 2022.
During the week of 8 April 2022 up to and including 14 April 2022 a total of 3,420,097 shares and depositary receipts were repurchased at an average price of €11.80 for a total amount of €40,340,048
For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme
To date the total consideration for shares and depositary receipts repurchased amounts to € 369.036.620 representing 73.8% of the overall share buyback programme.
This press release is published by ABN AMRO Bank N.V. and contains information that is to be made publicly available under Regulation (EU) No 596/2014 (Market Abuse Regulation)
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)19.5.2022 09:01:00 CEST | Press release
Dante Labs is a Global Leader in Genomics and Precision MedicineMainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC). Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to co
Regarding the approval of the key financial performance indicators for AB Klaipėdos nafta for the period of 2022-202419.5.2022 08:22:29 CEST | Press release
AB Klaipėdos nafta (hereinafter – the Company) hereby informs that the Government of the Republic of Lithuania on 18 May 2022 adopted the resolution No. 509 “Regarding the approval of the key financial performance indicators for state-owned enterprises for the period of 2022-2024”, which establishes the following performance indicators for the Company: Indicator202220232024Average annual adjusted EBITDA* Period 2022–2024 ≥ EUR 33.9 millionAnnual financial debt to equity ratio Period 2022–2024 limit 1.7–3.2 times * EBITDA less adjustment (temporary regulatory differences, temporary fluctuations in the fair value of financial derivatives, results from disposal or revaluation of non-current assets, compensations received for previous periods, other non-typical corrections). Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772
Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone19.5.2022 08:01:00 CEST | Press release
STOCKHOLM, SWEDEN – May 19, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has submitted a clinical trial application (CTA) to the Hungarian regulatory body OGÝEI for approval to initiate a Phase 2 clinical trial of its drug candidate golexanolone in patients suffering from primary biliary cholangitis. The study is planned to be conducted at several European clinical trial centers. Umecrine Cognition's drug candidate golexanolone represents a novel drug class that modulates the activity of the GABAA receptor in order to counteract cognitive impairment associated with liver disease and associated inflammation in the brain. Golexanolone is being developed in the indications of primary biliary cholangitis (PBC), which leads to inflammation and degeneration of the bile ducts, and hepatic encephalopathy (HE). The randomized, double-blind, placebo-controlled Phase 2 clinical trial will compare golexanolone to placebo in
Karolinska Developments portföljbolag Umecrine Cognition ansöker om start av klinisk fas 2-studie med golexanolon19.5.2022 08:01:00 CEST | Pressemelding
STOCKHOLM, SVERIGE 19 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Umecrine Cognition har lämnat in en ansökan (CTA) till den ungerska läkemedelsmyndigheten om godkännande att starta en klinisk fas 2-studie med läkemedelskandidaten golexanolon i patienter som drabbats av primär biliär kolangit. Studien planeras att genomföras vid ett flertal europeiska kliniska prövningscentra. Umecrine Cognitions läkemedelskandidat golexanolon tillhör en ny klass av läkemedel som modulerar aktiviteten i GABAA-receptorn i syfte att motverka kognitiva störningar som uppstår i samband med leversjukdom och associerad inflammation i hjärnan. Golexanolon utvecklas inom indikationerna primär biliär kolangit (PBC), som leder till inflammation och nedbrytning av gallgångarna, och hepatisk encefalopati (HE; leverkoma). Den randomiserade, dubbelblinda, placebokontrollerade kliniska fas 2-studien kommer att jämföra golexanolon mot placebo i upp till 150 patienter
GOGL – First Quarter 2022 Results19.5.2022 08:00:00 CEST | Press release
Golden Ocean Group Limited (NASDAQ: GOGL / OSE: GOGL) (the “Company” or “Golden Ocean”), the world's leading owner of large size dry bulk vessels, today announced its unaudited results for the quarter ended March 31, 2022. Highlights Net income of $125.3 million and earnings per share of $0.63 (basic) for the first quarter of 2022 compared with net income of $203.8 million and earnings per share (basic) of $1.02 for the fourth quarter of 2021.Adjusted EBITDA of $149.4 million for the first quarter of 2022, compared with $243.5 million for the fourth quarter of 2021.Reported TCE rates for Capesize and Panamax/Ultramax vessels of $24,778 per day and $23,693 per day, respectively, and $24,330 per day for the whole fleet in the first quarter of 2022. Estimated TCE rates inclusive of charter coverage calculated on a load-to-discharge basis, are approximately: $28,300 per day for 78% of Capesize available days and $27,500 per day for 77% of Panamax available days for the second quarter of 20